Latest news with #Ceftum
Business Standard
14-05-2025
- Business
- Business Standard
GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share
Glaxosmithkline Pharmaceutical advanced 3.21% to Rs 2,879.70 after the company's standalone net profit jumped 34.73% to Rs 260.14 crore on a 6.06% increase in revenue from operations to Rs 966.08 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore. On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24. Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country. The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer. Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the companys 100th Annual General Meeting. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
GSK Pharma share price: GlaxoSmithKline Pharmaceuticals (GSK Pharma) shares were in demand on Wednesday, May 14, 2025, with the scrip rallying up to 8.46 per cent to hit an intraday high of Rs 3,026.20 per share. At 11:10 PM, however, the GSK Pharma shares were off highs, and were trading 4.18 per cent higher at Rs 906.85 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 81,460.24 level. What sparked the up move in GSK Pharma share price? The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 (Q4FY25) results. For the quarter ended March 31, 2025 (Q4FY25), GSK Pharma reported a revenue of Rs 966 crore, a like-to-like growth of 6 per cent. The profit after tax (PAT) for the quarter stood at Rs 260 crore. Meanwhile, the company reported full year revenue of Rs 3,723 crore, a growth of 9 per cent from FY24. The PAT before exceptional items (bei) zoomed 32 per cent to Rs 915 crore, and Ebitda margins expanded 500 basis points (bps) to 31.4 per cent. Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.' 'We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,' Akshikar added. Furthermore, the company revealed that it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer. GSK Pharma dividend, record date The Board has recommended a final dividend of Rs 42 per equity share on face value of Rs 10 each for the year ended March 31, 2025, subject to approval of members at 100th Annual General Meeting (AGM). The Company has fixed Friday, May 30, 2025, as the 'Record Date' for determining entitlement of members to final dividend for FY25. About GSK Pharma GlaxoSmithKline (GSK) Pharmaceuticals is a global healthcare company specialising in vaccines, specialty medicines, and general medicines. It operates under GSK plc, a British multinational pharmaceutical corporation headquartered in London. GSK India, a subsidiary of GSK plc, is a biopharmaceutical company engaged in the development and marketing of vaccines and medicines, with a strong focus on infectious diseases, HIV, oncology, and immunology.\
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth
GlaxoSmithKline (GSK) Pharmaceuticals on Tuesday announced a 35 per cent year-on-year (YoY) increase in consolidated net profit for the March quarter (Q4FY25) to ₹262.87 crore, up from ₹194.48 crore in the same period last year. The company's revenue from operations rose 4.8 per cent YoY to ₹974.37 crore, from ₹929.80 crore in Q4FY24. The performance is attributed to strong growth across key product portfolios. Sequentially, the company's net profit declined 14.3 per cent, while revenue rose 2.6 per cent from ₹229.88 crore and ₹949.42 crore, respectively, reported in Q3FY25. GSK Pharma said that flagship brands within its general medicines portfolio — including Augmentin, Calpol, Ceftum and T-Bact — strengthened their market positions with share gains. Bhushan Ashikar, Managing Director, GSK Pharma, said the company's diversified portfolio of general medicines, specialty products and vaccines had shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement and rapid digital acceleration. 'This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers,' he added. Ashikar stated that the company will continue to focus on its innovative portfolio through the launch of oncology assets in the financial year (FY) 2025–26. 'The company is on track to launch Zejula (niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer,' GSK Pharma said in a public statement. In the vaccines segment, the company maintained its leadership within the private market, with its paediatric vaccines portfolio — including Boostrix, Varilrix and Havrix — despite inclusion in the National Immunisation Programme (NIP) and rising competition. 'Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country,' the company said. On Tuesday, GSK Pharma's stock rose 2.49 per cent, ending the day's trade at ₹2,789 on the Bombay Stock Exchange (BSE).
&w=3840&q=100)
Business Standard
24-04-2025
- Business
- Business Standard
GSK Pharma surges 10%, stock hits all-time high; Buy, sell or hold?
Thus far in the calendar year 2025, the stock price of GSK Pharma has zoomed 40 per cent, as against 1.8 per cent rise in BSE Sensex. GlaxoSmithKline Pharmaceuticals share price today: Shares of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit an all-time high of ₹3,147.45, surging 10 per cent on the BSE in Thursday's intra-day trade in an otherwise subdued market on expectations of healthy earnings. The stock of the multinational pharmaceutical company has surpassed its previous high of ₹3,087.95 touched on August 22, 2024. At 10:24 am, GSK Pharma was trading 9 per cent higher at ₹3,099.85, as compared to 0.15 per cent decline in the BSE Sensex. Thus far in the calendar year 2025, the stock has zoomed 40 per cent, as against 1.8 per cent rise in the benchmark index. Board meeting for Q4 results A meeting of the board of directors of GSK Pharma will be held on May 13, 2025 to consider the approval of audited financial results (standalone & consolidated) for the quarter/year ended 31st March 2025 and to recommend dividend, if any, on the equity shares of the company, amongst other things. Strong Q3 performance In the October to December quarter (Q3FY25), GSK Pharma demonstrated strong growth and sustained profitability. The company reported an 18 per cent year-on-year (YoY) increase in revenue from operations at ₹946 crore, while it achieved a profit after tax (PAT) of ₹229 crore. The quarter saw a strong performance across key product portfolios. Flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains. The company's innovative Respiratory portfolio, led by Nucala and Trelegy, achieved robust growth, further expanding patient access across India. ALSO READ | HUL share price rises 2% after posting Q4 results, but pare gains soon; Details here In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines. The adult vaccines division continues to gain momentum with Shingrix (Herpes Zoster Vaccine – recombinant, adjuvanted), as the company spearheads the expansion of adult immunisation in India. Opportunities in Adult vaccination In India, interest in adult or adolescent vaccination has historically been low despite the Universal Immunisation Programme's success. However, COVID-19 vaccination initiatives have added momentum to discussions around adult vaccination. With increased life expectancy and a growing geriatric population in India, healthy ageing is emerging as a key focus area. A major intervention for healthy ageing continues to be preventive health led by vaccination strategies. Adult vaccination is at a nascent stage in India with a large potential for growth. For instance, the virus that causes Shingles affects over 90 per cent of adults and may get reactivated in the form of shingles disease, the company said in its FY24 annual report. Technical view on stock On Thursday, April 17, GSK Pharma stock witnessed the formation of a 'Golden Cross', commonly known as 'Golden Crossover' on the daily charts. The 'Golden Cross' formation means that the 50-DMA of that particular stock or index has crossed over the 200-DMA. This, in general, implies that the short-term moving average is in ascending angle, thus indicating likely support at higher levels. Even as the stock has seen a 'Golden Crossover', GSK Pharma at present is seen testing resistance around its super trend line on the daily chart at ₹2,930. Break and sustained trade above the same shall open the doors for a likely rally towards ₹3,180, with some interim resistance around ₹3,045 levels. The long-term chart suggests the stock can potentially target ₹3,500 levels in the coming months. About GlaxoSmithKline Pharmaceuticals GlaxoSmithKline Pharmaceuticals is a subsidiary of GSK plc, a science-led global healthcare company that aims to unite science, technology, and talent to get ahead of disease together. The company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals.
